

## *Care* – the new name for high-performance plastics in medical technology

The new *Care* Product Line from Evonik Industries includes a wide range of high-performance polymers utilized in a variety of medical applications. The biocompatibility of our VESTAMID® *Care* and TROGAMID® *Care* Product Lines has been proven in comprehensive tests by independent testing institutes, and our materials meet USP Class VI requirements.

We offer a range of customized product solutions depending on the technical requirements for the medical device, whether flexible or rigid, transparent or translucent. For example, *Care* products are used in a variety of medical applications, such as in catheters for vascular treatment, in surgical instruments, or as selector valves for infusion equipment.

"When designing our *Care* products, we work closely with our customers to offer custom solutions as well as to pick up on and play out trends in the medical industry as they occur," says Christiane Röhnke, Medical Devices Business Manager.

Thanks to decades of experience, Evonik is one of the leaders in polymer design technology. Evonik assists its customers throughout the product development cycle—from material development to the manufacturing of the finished product.



### Image Caption

One of many application areas:  
Hearing aids

March 13, 2012

### Thomas Lange

Communications

High Performance Polymers

Phone: +49 2365-49-9227

Fax: +49 2365-49-809227

thomas.lange2@evonik.com

### Evonik Industries AG

Rellinghauser Strasse 1-11

45128 Essen

Germany

[www.evonik.com/medical](http://www.evonik.com/medical)

### Chairman of the Supervisory Board

Wilhelm Bonse-Geuking

### Executive Board

Dr. Klaus Engel, Chairman

Dr. Wolfgang Colberg,

Dr. Thomas Haeberle, Thomas Wessel,

Patrik Wohlhauser, Dr. Dahai Yu

Registered Office: Essen

Register Court: Essen Local Court

Commercial Registry B 19474

VAT ID no. DE 81116003

**Company information**

Evonik, the creative industrial group from Germany, is one of the world leaders in specialty chemicals. Its activities focus on the key megatrends health, nutrition, resource efficiency and globalization. In 2010 about 80 percent of the Group's chemicals sales came from activities where it ranks among the market leaders. Evonik benefits specifically from its innovative prowess and integrated technology platforms.

Evonik is active in over 100 countries around the world. In fiscal 2010 more than 34,000 employees generated sales of around €13.3 billion and an operating profit (EBITDA) of about €2.4 billion.

**Disclaimer**

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

**Evonik Industries AG**

Rellinghauser Strasse 1-11  
45128 Essen  
Germany  
[www.evonik.com/medical](http://www.evonik.com/medical)

**Chairman of the Supervisory Board**

Wilhelm Bonse-Geuking

**Executive Board**

Dr. Klaus Engel, Chairman  
Dr. Wolfgang Colberg,  
Dr. Thomas Haeberle, Thomas Wessel,  
Patrik Wohlhauser, Dr. Dahai Yu

Registered Office: Essen  
Register Court: Essen Local Court  
Commercial Registry B 19474  
VAT ID no. DE 81116003